Liquid Biopsy Market Analysis

ID: MRFR/HC/0239-CR

171 Pages

Kinjoll Dey

February 2023

Liquid Biopsy Market Research Report By Application (Cancer Diagnosis, Treatment Monitoring, Recurrence Monitoring, Clinical Trials, Research Applications), By Sample Type (Blood, Urine, Saliva, Pleural Fluid, Cerebrospinal Fluid), By Technology (Next Generation Sequencing, Digital PCR, Microfluidics, Exosome Isolation, Circulating Tumor Cells), By End Use (Hospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast ... read more

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Analysis

In-depth Analysis of Liquid Biopsy Market Industry Landscape

Collaboration and partnership strategies have emerged as crucial components in shaping the landscape of the liquid biopsy market. This trend, particularly evident among major players, not only propels the market forward but also creates opportunities for new entrants. An exemplary collaboration between MD Anderson and Guardant Health illustrates the symbiotic nature of such partnerships. In this case, the integration of liquid biopsy into oncology care is a shared goal. Guardant gains exposure and product launch capabilities, leveraging the credibility of MD Anderson in the field of cancer care. Simultaneously, MD Anderson benefits by reducing treatment costs. This partnership also establishes a robust feedback mechanism, enhancing ongoing product development. Similar collaborations, such as the one between BGI and Clearbridge Bio Medics, focusing on the development of the China CTC liquid biopsy market, showcase the advantages reaped by both entities through skill-sharing and risk and cost reduction. Such collaborative efforts become avenues for mutually beneficial ventures, contributing to overall market growth.

The support from public organizations has further bolstered the liquid biopsy market, particularly benefiting small start-ups by lowering development costs and risk sharing. In 2017, for instance, the German genetic testing firm CeGaT received government funding for the development of liquid biopsy technology for analyzing circulating tumor DNA, underscoring the role of public backing in driving innovation.

Firms with a robust research foundation, especially those engaged in cross-domain research, are well-positioned to thrive in the liquid biopsy market. The surge in research and development investments is anticipated to be a key driver, expanding the application of liquid biopsy to various diseases, including autoimmune conditions and rarer biomarkers. This evolving landscape presents opportunities for enhanced market presence and increased product exposure through continual product development.

While the liquid biopsy market has predominantly been dominated by developed regions, there is significant potential for growth in the developing world. The relatively low penetration in these regions presents an untapped market, offering the opportunity to drive down costs through economies of scale. Market penetration in developing regions is a strategic move to harness the advantages of being a first mover and developing economies of scale. The premium associated with being a pioneer in the liquid biopsy market further underscores the importance of early market entry.

Collaboration and partnerships, supported by research investments and expanding applications, are steering the liquid biopsy market forward. The dynamics of such collaborations not only foster innovation and reduce costs but also pave the way for market expansion into previously uncharted territories. The evolving nature of the liquid biopsy market positions it as a realm of constant opportunity, especially for those embracing collaboration, research, and strategic market penetration.

Market Highlights

Author

Kinjoll Dey

Research Analyst Level I

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch

FAQs

What is the projected growth of the Liquid Biopsy market?

The Liquid Biopsy market is the expected increase in total market value of 27.34 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Liquid Biopsy market?

Liquid Biopsy market size was valued at approximately 9.1 billion USD in 2024. This figure will reach 27.34 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Liquid Biopsy market?

Liquid Biopsy market is expected to grow at a CAGR of 10.52% between 2025 and 2035.

How much will the Liquid Biopsy market be worth by 2035?

Liquid Biopsy market is expected to be worth of 27.34 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Liquid Biopsy market perform over the next 10 years?

Over the next 10 years the Liquid Biopsy market is expected to shift from usd billion 9.1 to 27.34 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

Which region is expected to dominate the Global Liquid Biopsy Market in 2024?

North America is expected to dominate the Global Liquid Biopsy Market with a value of 2.5 USD Billion in 2024.

What will be the market size of the Global Liquid Biopsy Market in Europe by 2035?

The market size for the Global Liquid Biopsy Market in Europe is projected to reach 3.8 USD Billion by 2035.

What is the forecasted market size for Cancer Diagnosis within the Global Liquid Biopsy Market in 2035?

The market size for Cancer Diagnosis is expected to reach 5.9 USD Billion in 2035.

Who are some of the major players in the Global Liquid Biopsy Market?

Major players in the Global Liquid Biopsy Market include GRAIL, Natera, Foundation Medicine, and Thermo Fisher Scientific.

What is the anticipated market size for Treatment Monitoring in 2024?

The anticipated market size for Treatment Monitoring in 2024 is 1.3 USD Billion.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

According to Market Research Future Analysis, The liquid biopsy market size was $9.10 billion in 2024 and is projected to reach $27.34 billion by 2025, with a CAGR of 10.52% from 2025 to 2035. The market is driven by the increasing prevalence of cancer, technological advancements, and the demand for non-invasive diagnostic methods. Liquid biopsies are preferred for monitoring treatment responses and detecting recurrences, aligning with the shift towards personalized medicine. Key players are innovating to enhance diagnostic capabilities, supported by regulatory approvals and collaborations.

Key Market Trends & Highlights

The Liquid Biopsy Market is experiencing significant growth driven by technological advancements and increasing cancer prevalence.

Market Size in 2024: 9.10 USD Billion; Expected to reach 27.34 USD Billion by 2035. CAGR from 2025 to 2035: 10.52%; indicating robust growth potential. Cancer Diagnosis segment expected to reach 2.2 USD Billion in 2024, dominating the market. North America projected to hold a market value of 2.5 USD Billion in 2024, leading regional growth.

Market Size & Forecast

2024 Market Size	USD 9.10 Billion
2035 Market Size	USD 27.34 Billion
CAGR (2025-2035)	10.52%
Largest Regional Market Share in 2024	North America.

Major Players

Key players include GRAIL, Natera, Foundation Medicine, Exact Sciences, Thermo Fisher Scientific, and Illumina.

Market Trends

Technological advancements and an increasing emphasis on early cancer diagnosis are driving significant trends in the global liquid biopsy market. Due to their non-invasive nature, liquid biopsy techniques are gaining increasing preference for monitoring treatment response and detecting cancer recurrence.

This trend is primarily driven by the increasing prevalence of cancer and the growing awareness of personalized medicine, which is compelling healthcare providers and researchers to pursue innovative diagnostic solutions.

Liquid Biopsy Market Market Drivers

Rising Incidence of Cancer

The increasing prevalence of cancer globally serves as a primary driver for the Global Liquid Biopsy Market Industry. As cancer cases rise, the demand for early detection and monitoring solutions intensifies. Liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, allowing for the analysis of circulating tumor DNA. For instance, the World Health Organization indicates that cancer cases are expected to reach 30 million by 2040. This growing patient population is likely to propel the market, with projections estimating the Global Liquid Biopsy Market to reach 8.9 USD Billion in 2024 and potentially 22.9 USD Billion by 2035.

Market Segment Insights

Liquid Biopsy Market Application Insights

The Global Liquid Biopsy Market in terms of application has shown considerable growth and importance, with various areas such as Cancer Diagnosis, Treatment Monitoring, Recurrence Monitoring, Clinical Trials, and Research Applications driving this trend.

In 2024, the valuation for Cancer Diagnosis is expected to reach approximately 2.2 USD Billion, solidifying its position as the dominant segment within the market. This is largely due to the increasing prevalence of cancer and the necessity for early detection, which enhances treatment outcomes and helps tailor therapy for patients.

Treatment Monitoring, valued at around 1.3 USD Billion in 2024, plays a critical role in assessing therapeutic effectiveness and adjusting strategies promptly. As treatment regimens become more personalized, this segment is vital to enabling healthcare professionals to monitor patients' responses effectively through non-invasive means.

Recurrence Monitoring is anticipated to hold a value of 0.8 USD Billion in the same year, and it is significant for patients who have undergone cancer treatment, providing essential follow-up insights that can affect long-term survival rates.

Clinical Trials, also valued at 0.8 USD Billion, contribute significantly by facilitating innovative therapies and ensuring safety while enhancing the drug development process through insights derived from liquid biopsy techniques. Additionally, Research Applications, while smaller with a value of 0.41 USD Billion, are crucial in advancing the understanding of cancer biology and the development of new diagnostic methods, thus laying the groundwork for future breakthroughs.

Over the years, the importance of these applications has become increasingly clear as they support a wide range of diagnostic and therapeutic advancements. With the Global Liquid Biopsy Market anticipated to expand, these application segments will likely continue to evolve, driving the industry forward and reflecting the shift toward more precise patient care within the healthcare ecosystem.

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Liquid Biopsy Market Sample Type Insights

The global liquid biopsy market growth is expected to be significant, with a projected valuation of 5.51 USD Billion by 2024. This market is essential for non-invasive <a href="https://www.marketresearchfuture.com/reports/cancer-diagnostics-market-1962">cancer diagnostics</a>, enabling real-time monitoring of disease progression and therapeutic responses

The market segmentation based on Sample Type includes Blood, Urine, Saliva, Pleural Fluid, and <a href="https://www.marketresearchfuture.com/reports/cerebrospinal-fluid-management-devices-market-7196">Cerebrospinal Fluid</a>, each contributing uniquely to advancements in medical diagnostics.

As the market matures, trends indicate increasing adoption of these sample types driven by technological innovations and a growing emphasis on personalized medicine strategies within the Global Liquid Biopsy Market. The industry's growth will continue to be fueled by ongoing Research and Development investments and the rising demand for early-stage cancer diagnostics.

Liquid Biopsy Market Technology Insights

The global liquid biopsy market is growing at a significant rate due to technological advancements, with an estimated value of US$5.51 billion by 2024 and is expected to reach US$15.0 billion by 2035. This segment encompasses several key technologies that enhance diagnostic capabilities and patient care, with a significant focus on innovations such as <a href="https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354">Next Generation Sequencing</a> and <a href="https://www.marketresearchfuture.com/reports/pcr-technology-market-21873">Digital PCR</a>, which are pivotal for precise cancer profiling and monitoring. For stakeholders evaluating liquid biopsy growth, these technology-driven developments underscore expanding adoption across clinical and research applications.

Furthermore, <a href="https://www.marketresearchfuture.com/reports/microfluidic-devices-market-954">Microfluidics </a>plays a vital role in enabling efficient sample processing and analysis, while <a href="https://www.marketresearchfuture.com/reports/exosomes-market-21546">Exosome </a>Isolation techniques are becoming increasingly important for understanding tumor biology and biomarker discovery.

Circulating Tumor Cells

<a href="https://www.marketresearchfuture.com/reports/circulating-tumor-cell-market-1362">Circulating Tumor Cells</a> are at the forefront of research, offering insights into cancer progression and treatment response. The Global Liquid Biopsy Market statistics indicate that this sector not only addresses the growing demand for non-invasive diagnostic solutions but also presents numerous opportunities for personalized medicine, ultimately improving patient outcomes on a global scale. With technology continually evolving, the industry is positioned for significant market growth, paving the way for novel applications in oncology and beyond.

Liquid Biopsy Market End Use Insights

The Global Liquid Biopsy Market, particularly in the End Use segment, has shown substantial growth potential, with a market value expected to reach 5.51 billion USD by 2024 and is projected to evolve significantly by 2035. Various applications within this segment, including Hospitals, Diagnostic Laboratories, Research Institutes, and liquid biopsy companies, play crucial roles in driving this growth.

Hospitals are increasingly adopting liquid biopsy procedures for non-invasive testing and early cancer detection, contributing to the overall market expansion. Diagnostic Laboratories are essential for providing specialized testing services which have become more refined with technological advancements.

Research Institutes are focusing on innovative methodologies to enhance liquid biopsy applications, thereby broadening its utility in precision medicine. Lastly, Pharmaceutical Companies leverage liquid biopsy data for drug development and monitoring treatment responses, highlighting its significance in therapeutic areas.

Get more detailed insights about Liquid Biopsy Market Research Report - Global Forecast to 2035

Regional Insights

The Global Liquid Biopsy Market stands as a noteworthy entity within the healthcare industry, with projections indicating a valuation of 5.51 USD Billion in 2024 and reaching 15.0 USD Billion by 2035. The Regional segment unveils a hierarchy where North America emerges as a dominant player, holding a substantial valuation of 2.5 USD Billion in 2024, expected to grow to 6.8 USD Billion by 2035, thus showcasing its majority holding in the market.

Europe follows with a valuation of 1.4 USD Billion in 2024, anticipated to expand to 3.8 USD Billion by 2035, indicating its significant role in market growth driven by advanced healthcare infrastructure and high R investment.

APAC accounts for a valuation of 1.2 USD Billion in 2024, with an eventual rise to 3.3 USD Billion by 2035, supported by increasing cancer prevalence and growing awareness of non-invasive diagnostic options. South America and MEA represent the smaller segments, valued at 0.3 USD Billion and 0.11 USD Billion respectively in 2024, but still providing opportunities due to increasing healthcare investments and rising interest in precision medicine solutions.

The significant growth in these regions is driven by rising incidences of cancer, technological advancements in liquid biopsy methods, and a focus on personalized medicine, thus enabling the Global Liquid Biopsy Market revenue to flourish across diverse geographical landscapes.

Liquid Biopsy Market Region

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Key Players and Competitive Insights

The global liquid biopsy market is witnessing significant growth due to the increasing incidence of cancer and the growing demand for minimally invasive diagnostic solution technologies that enable the detection of cancer biomarkers from blood samples, providing a safe and effective alternative to traditional tissue biopsy.

This market is characterized by a dynamic competitive landscape, featuring various players vying for market share through innovations in technology, strategic partnerships, and expanding their product offerings. The liquid biopsy companies engaged in this space are focusing on developing highly sensitive and specific assays to improve patient outcomes.

The emergence of personalized medicine and precision health further enhances the relevance of liquid biopsies, increasing competition among market participants who aim to establish their foothold and address the unmet clinical needs of healthcare providers.

GRAIL

GRAIL stands out in the Global Liquid Biopsy Market due to its focus on early detection of cancer through innovative blood testing technologies. The company pioneering genomic sequencing methods combined with advanced artificial intelligence algorithms to identify various types of cancers at their earliest stages, which significantly improves patient prognosis and therapy options.

GRAIL's unique approach to liquid biopsy not only distinguishes it from competitors but also positions it as a leader in the market, with a robust pipeline of ongoing clinical studies validating its flagship products. The company has established strong partnerships with clinical institutions, enhancing its research capabilities and expanding its market presence.

GRAIL's cutting-edge technology and commitment to advancing liquid biopsy assays reflect its inherent strengths in attaining a commanding position in this evolving industry.

Natera

Natera is another key player in the Global Liquid Biopsy Market, focusing on reproductive health and oncology with a strong emphasis on non-invasive testing solutions. The company's core product offerings include theSignatera personalized mRNA tumor antigen assay, which is designed to monitor minimal residual disease and detect recurrences in cancer patients, thereby contributing to better patient management strategies.

Natera's market presence is bolstered by its advanced laboratory services and a network of partnerships with healthcare providers, which enhance its ability to deliver comprehensive genomic insights. The company has engaged in strategic collaborations and acquisitions to expand its technology platform and enhance its RD capabilities.

Furthermore, Natera's emphasis on robust clinical validation of its products supports its credibility in the market, empowering it to leverage its strengths in precision medicine as it addresses a growing demand for advanced liquid biopsy solutions on a global scale.

Key Companies in the Liquid Biopsy Market market include

Industry Developments

Recent developments in the Global Liquid Biopsy Market have seen significant advancements, with liquid biopsy companies like GRAIL and Exact Sciences pushing innovative technologies and applications. Major players are expanding their portfolios and improving diagnostic capabilities for early cancer detection.

In September 2023, Natera announced the successful launch of a new assay aimed at enhancing non-invasive prenatal testing, showcasing a potential overlap in liquid biopsy technology. Meanwhile, in August 2023, a collaboration between Foundation Medicine and Roche focused on integrating liquid biopsies into their existing genomic profiling services, emphasizing the increased relevance of these tests in personalized medicine.

On the mergers and acquisitions front, Thermo Fisher Scientific acquired Brammer Bio in December 2022, with implications for its liquid biopsy capabilities. Growth in market valuation continues to accelerate, attributed to rising collaborations across liquid biopsy companies, including Guardant Health and Illumina, as they enhance product offerings and expand their reach in the oncology segment.

Significant happenings over the last few years include the establishment of regulatory frameworks facilitating liquid biopsy integration into clinical practices, further confirming their positioning in oncology diagnostics on a global scale.

Future Outlook

Liquid Biopsy Market Future Outlook

The Liquid Biopsy Market is projected to grow at an 11.60% CAGR from 2025 to 2035, driven by advancements in technology, increasing cancer prevalence, and demand for non-invasive diagnostics.

New opportunities lie in:

Develop innovative liquid biopsy assays for early cancer detection. Expand partnerships with healthcare providers to enhance market penetration. Invest in AI-driven analytics for improved data interpretation and patient outcomes.

By 2035, the Liquid Biopsy Market is expected to achieve substantial growth, reflecting its critical role in personalized medicine.

Market Segmentation

Liquid Biopsy Market End Use Outlook

Hospitals
Diagnostic Laboratories
Research Institutes
Pharmaceutical Companies

Liquid Biopsy Market Technology Outlook

Next Generation Sequencing
Digital PCR
Microfluidics
Exosome Isolation
Circulating Tumor Cells

Liquid Biopsy Market Application Outlook

Cancer Diagnosis
Treatment Monitoring
Recurrence Monitoring
Clinical Trials
Research Applications

Liquid Biopsy Market Sample Type Outlook

Blood
Urine
Saliva
Pleural Fluid
Cerebrospinal Fluid

Report Scope

Report Attribute/Metric Source	Details
MARKET SIZE 2023	8.1 USD Billion
MARKET SIZE 2024	9.10 (USD Billion)
MARKET SIZE 2035	27.34 USD Billion
CAGR (2025-2035)	10.52% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Forecast Period	2025 - 2035
HISTORICAL DATA	2019 - 2023
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	GRAIL, Natera, Foundation Medicine, Exact Sciences, Thermo Fisher Scientific, Avantor, ArcherDX, Roche, Medpace, Illumina, Guardant Health, Qiagen, Freenome, Biocept
SEGMENTS COVERED	Application, Sample Type, Technology, End Use, Regional
KEY MARKET OPPORTUNITIES	Increasing cancer prevalence, Non-invasive diagnostic advancements, Rising demand for personalized medicine, Technological innovations in assays, Expanding applications in clinical trials
KEY MARKET DYNAMICS	increasing cancer prevalence , technological advancements , non-invasive testing preference , regulatory approvals and reimbursement , rising research and development investments
COUNTRIES COVERED	North America, Europe, APAC, South America, MEA